Kate Dellorusso, an analyst from LifeSci Capital, has initiated a new Buy rating on Upstream Bio, Inc. (UPB).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kate Dellorusso has given his Buy rating due to a combination of factors indicating that Upstream Bio is well positioned for meaningful commercial success with verekitug in asthma. Her survey of 50 high-volume U.S. asthma specialists shows that biologic usage is already substantial in moderate-to-severe patients, and physician enthusiasm for TSLP inhibition is notably high, supported by Tezspire’s growing real-world validation and label expansions such as CRSwNP. Within this environment, clinicians appear eager to add long-acting TSLP inhibitors to their toolkits, and specifically express interest in verekitug as a future treatment option.
Kate Dellorusso also emphasizes that the upcoming Phase 2 VALINAT readout is a key catalyst, with survey responses suggesting that achieving Tezspire-like efficacy at a 12-week dosing interval would be sufficient to drive strong uptake, and any credible efficacy at a 24-week interval would provide incremental upside. She views long-acting biologics as the next evolution in asthma care, given the importance of durable symptom control for adherence and persistence. In her view, these clinical and market dynamics, combined with the current competitive landscape and physicians’ readiness to adopt verekitug if the data are supportive, justify a favorable risk–reward profile and underpin her Buy rating on UPB.
According to TipRanks, Dellorusso is an analyst with an average return of -6.2% and a 25.00% success rate.
In another report released on January 9, Evercore ISI also maintained a Buy rating on the stock with a $40.00 price target.